Skip to main content
. 2018 May 17;1(6):e40. doi: 10.1002/hsr2.40

Figure 2.

Figure 2

Relapse‐free survival of high, medium, and low groups. Relapse‐free survival rates were 61.2% in high VASH1 group, 47.6% in medium VASH1 group, and 32.1% in low VASH1 group. High VASH1 group had better prognosis than had low VASH1 level patients. P = .056, log‐rank test. VASH1 indicates vasohibin‐1